Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis

Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis

Background: Janus kinase (JAK) inhibitors are promising for inflammatory bowel diseases (IBDs), but their long-term safety, including risks of nonmelanoma skin cancer (NMSC), is uncertain. Objectives: The objective of the study was to conduct a systematic review and meta-analysis to examine the risk...

Full description

Bibliographic Details
Main Authors: Chuen-Huei Liu, Wen-Hsuan Hou, Pi-Chu Lin, Yi-No Kang, Wei-Ting Liu, Su-Ru Chen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-09-01
Series:Dermatologica Sinica
Subjects:
adverse event
inflammatory bowel disease
janus kinase inhibitor
nonmelanoma skin cancer
safety
Online Access:https://journals.lww.com/10.4103/ds.DS-D-23-00241

Internet

https://journals.lww.com/10.4103/ds.DS-D-23-00241

Similar Items